v3.26.1
Net Income (Loss) per Share - Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Income (Loss) per Share of Class A Common Stock (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Numerator:    
Net income (loss) $ 24,134 $ (6,217)
Less: Net loss attributable to noncontrolling interests 0 (1,125)
Net income (loss) attributable to common shareholders of vTv Therapeutics Inc., basic 24,134 (5,092)
Numerator:    
Net income (loss) 24,134 (6,217)
Less: Net loss attributable to noncontrolling interests 0 (1,125)
Net income (loss) attributable to common shareholders of vTv Therapeutics Inc, diluted $ 24,134 $ (5,092)
Class A Common Stock    
Denominator:    
Weighted average vTv Therapeutics Inc. Class A common stock (in shares) 12,409,278 6,582,844
Basic net loss per share of vTv Therapeutics Inc. Class A common stock (in usd per share) $ 1.94 $ (0.77)
Denominator:    
Weighted average vTv Therapeutics Inc. Class A common stock (in shares) 14,634,420 6,582,844
Diluted net income (loss) per share of vTv Therapeutics Inc. Class A common stock (in usd per share) $ 1.65 $ (0.77)